How to Cite
Abstract
Nowadays, the success of chemotherapy for breast cancer demonstrates high sensitivity and effectiveness, and therefore it has become possible to increasingly use breast conserving surgery treatment. Genetically associated breast cancer patients it is a separate clinical group, the treatment of which should take into account the carriage of mutations in the BRCA1, BRCA2, CHEK2 genes. Until now, the possibility of breast conserving surgery in such patients remains debatable. After all, we often talk in such patients not only about the need to perform a mastectomy, but also about a prophylactic mastectomy from the contralateral side to minimize the risks of cancer. Is it acceptable to perform breast conserving treatment in such patients? This article analyzes the experience of well-known foreign oncologists, as well as analyzes their own experience of the Department of Oncology and Radiology RUDN University, Head of the Department of Oncology and Reconstructive Surgery of the Mammary Gland and Skin, P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation.
References
Клинические рекомендации американского общества онкологов (NCCN) лечения злокачественных новообразований в 2021 г. [NCCN Clinical Practice Guidelines in Oncology] Доступно по: https://www.nccn.org
Тюляндин С.А., Жукова Л.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2021 (том 11). 09. [Tyulyandin S.A., Zhukova L.G., Koroleva I.A. Practical recommendations for the drug treatment of breast cancer. Malignant Tumors // Practical Guidelines RUSSCO. 2021; 11. 09 (In Russ.)]
Клинические рекомендации по диагностике// P и лечению опухолей (взрослые) АОР., 2021. Доступно по: http://www.oncology.ru/association/clinical-guidelines/
Клинические рекомендации европейского общества онкологов (ESMO) лечения злокачественных новообразований в 2021 г. [Prevention and screening in brca mutation carriers and other breast/ovarian hereditary cancer syndromes: esmo clinical practice guidelines] Доступно по: https://www.esmo.org/
Имянитов Е.Н., Соколенко А.П., Берлев И.В. и др. Носительство мутаций в генах BRCA1 и BRCA2 у здоровых женщин и мужчин: ДНК-тестирование, диагностические мероприятия и профилактика рака // Вопросы онкологии. 2017;63(2):190–198. [Imyanitov E.N., Sokolenko A.P., Berlev I.V. et al. Presence of BRCA1 and BRCA2 in healthy women and men: DNA testing, diagnostic activities and cancer prevention // Voprosy oncologii. 2017;63(2):190–198. (In Russ.)]
McGuire V, Felberg A, Mills M et al. Relation of Contraceptive and Reproductive History to Ovarian Cancer Risk in Carriers and Noncarriers of BRCA1 Gene Mutations // American Journal of Epidemiology. 2004;160(7):613–618.
Metcalfe K, Gershman S, Ghadirian P et al. Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers // J Clin Oncol. 2004;22:2328–2335.
Metcalfe K, Gershman S, Lynch HT et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers // British journal of cancer. 2011;104(9):1384–1392.
Metcalfe K, Gershman S, Ghadirian P et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis // BMJ (Clinical research ed.). 2014;348:226.
Nasim Mavaddat, Susan Peock et al. Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE // J Natl Cancer Inst;2013;105:812–822.
Kramer I, Hooning MJ, Mavaddat N et al. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk // Am J Hum Genet. 2020 Nov 5;107(5):837–848. doi:10.1016/j.ajhg.2020.09.001
Pierce LP, Levin AM, Rebbeck TR et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer // J Clin Oncol. 2006;24(16):2437–43. doi:10.1200/JCO.2005.02.7888
Co M, Liu T, Leung J et al. Breast Conserving. Surgery in BRCA mutation carriers — A Systematic Review, Clinical Breast Cancer. 2019. doi:https://doi.org/10.1016/j.clbc.2019.07.014
Trimboli RM, Schiafno S, Sardanelli F. In BRCA mutation carriers breast conserving surgery may not be the best choice // Breast Cancer Res Treat. 2019;178(1):245–246. doi:10.1007/s10549-019-05373-y
Antonis Valachis, Andreas D, Nearchou, Pehr Lind. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis // Breast Cancer Res Treat. 2014;144(3):443–55. doi:10.1007/s10549-014-2890-1
Desmond A, Kurian AV, Gabree M et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment // JAMA Oncol. 2015;1(7):943–951.
Солодкий В.А., Ходорович О.С., Калинина-Масри А.А. и др. CHEK2-ассоциированный рак молочной железы // Вестник российского научного центра рентгенорадиологии. 2019;19(2):40–51. [Solodkiy V.A., Khodorovich O.S., Kalinina-Masri A.A. et al. CHEK2-mutation associated breast cancer // Vestnik rossijskogo nauchnogo centra rentgenoradiologii. 2019;19(2):40–51 (In Russ.)]
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021